BFM
VIR icon

Boothbay Fund Management’s Vir Biotechnology VIR Stock Holding History

Boothbay Fund Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-259
Closed -$1.33M – 2134
2021
Q1 		$1.33M Sell
259
-20
-7% -$1.08K 0.05% 477
2020
Q4 		$747K Buy
+279
New +$9.07K 0.03% 607

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Boothbay Fund Management's VIR Position: Q1 2026 in Review

Boothbay Fund Management reduced its Vir Biotechnology (VIR) stake by 53% in Q1 2026, selling an estimated $577K and leaving 63,227 shares worth $567K. The position accounts for 0.01% of the portfolio, ranked #1272.

Boothbay Fund Management first reported a position in VIR in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.99M in Q1 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Boothbay Fund Management held 63,227 shares of Vir Biotechnology worth $567K as of Q1 2026.
  • Boothbay Fund Management sold 72,474 Vir Biotechnology shares in Q1 2026, an estimated $577K.
  • Vir Biotechnology made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1272 holding.
  • Boothbay Fund Management first reported a position in Vir Biotechnology in Q2 2020 and has held it in 8 quarters since.
  • Boothbay Fund Management's Vir Biotechnology position peaked at $1.99M in Q1 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.